Efficacy of Ramucirumab Versus Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma
The study examined the therapeutic efficacy of ramucirumab compared with that of sorafenib as subsequent systemic therapy for patients with HCC. The PFS was significantly longer in the ramucirumab group than in the sorafenib group. T
